Biofrontera AG (BFRA) Stock Analysis
DELISTED 2022
What happened to Biofrontera AG (BFRA) stock?
Biofrontera AG (BFRA) no longer trades on public markets. It was delisted in March 2022. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
- Delisting date:
- March 2022
- Last recorded price (historical):
- $2.67 (last quote on record before the March 2022 delisting; historical, not a current quote)
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Biofrontera AG (BFRA). Biofrontera AG is a German biopharmaceutical company focusing on dermatological treatments, particularly for sun-induced skin conditions like actinic keratosis, with its flagship product Ameluz.
Last analyzed: Jun 15, 2026Biofrontera AG (BFRA) Healthcare & Pipeline Overview
Biofrontera AG ADR Information Sponsored
Biofrontera AG (BFRA) trades in the U.S. as an American Depositary Receipt (ADR).
- ADR Level: 2
- ADR Ratio: 1:1
More about this archive record
Can I still buy BFRA shares?
No. BFRA stopped trading on public markets in March 2022, so the shares are not available through a broker. Anything you see quoted for BFRA elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before BFRA stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Biofrontera AG. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.